Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles

Bioconjugate Chemistry

Volumn 25, Issue 5, 2014, Pages 879-887

  Seifert, Oliver ^a   Pollak, Nadine ^a   Nusser, Anja ^a,d   Steiniger, Frank ^b   Rüger, Ronny ^c   Pfizenmaier, Klaus ^a   Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOMES; TUMORS;

ANTI-EGFR; CLINICAL STUDY; DEATH-RECEPTOR; FUNCTIONALIZED; HALF LIVES; LIPOSOMAL NANOPARTICLES; NON-TARGETED; SINGLE-CHAIN FV; TARGETED DELIVERY; TUMOUR CELLS;

CELL DEATH;

BORTEZOMIB; DEATH RECEPTOR 4; DEATH RECEPTOR 5; IMMUNOLIPOSOME; NANOCARRIER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; LIPOSOME; NANOPARTICLE; TNFSF10 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL KILLING; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PLASMA HALF LIFE; PROTEIN EXPRESSION; ANIMAL; CELL DEATH; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; INBRED MOUSE STRAIN; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PARTICLE SIZE; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIPOSOMES; MICE; MICE, INBRED STRAINS; MICE, NUDE; MODELS, MOLECULAR; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PARTICLE SIZE; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84901013716     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc400517j     Document Type: Article

References (30)

1. Johnstone, R. W., Frew, A. J., and Smyth, M. J. (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy Nat. Rev. Cancer 8, 782-798
2. Yang, A., Wilson, N. S., and Ashkenazi, A. (2010) Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation Curr. Opin. Cell Biol. 22, 837-844
3. Mellier, G., Huang, S., Shenoy, K., and Pervaiz, S. (2010) TRAILing death in cancer Mol. Aspects Med. 31, 93-112
4. den Hollander, M. W., Gietema, J. A., de Jong, S., Walenkamp, A. M., Reyners, A. K., Oldenhuis, C. N., and de Vries, E. G. E. (2012) Translating TRAIL-receptor targeting agents to the clinic Cancer Lett. 322, 194-201
5. LeBlanc, H. N. and Ashkenazi, A. (2003) Apo2L/TRAIL and its death and decoy receptors Cell Death Differ. 10, 66-75
6. Schneider, B., Münkel, S., Krippner-Heidenreich, A., Grunwald, I., Wels, W. S., Wajant, H., Pfizenmaier, K., and Gerspach, J. (2010) Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins Cell Death Dis. 1, e68
7. Kriegl, L., Jung, A., Horst, D., Rizzani, A., Jackstadt, R., Hermeking, H., Gallmeier, E., Gerbes, A. L., Kirchner, T., Göke, B., and De Toni, E. N. (2012) Microsatellite instability, KRAS mutations and cellular distibution of TRAIL-receptors in early stage colorectal cancer PLoS One 7, e51654
8. Micheu, O., Shirley, S., and Dufour, F. (2013) Death receptors as targets in cancer Br. J. Pharmacol. 169, 1723-1744
9. Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., ODwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnaya, T. M., Lum, B. L., Askenazi, A., Jubb, A. M., and Mendelson, D. S. (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer J. Clin. Oncol. 28, 2839-2846
10. Soria, J. C., Smit, E., Khayat, D., Besse, B., Yang, X., Hsu, C. P., Reese, D., Wiezorek, J., and Blackhall, F. (2010) Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer J. Clin. Oncol. 28, 1527-1533
11. Soria, J. C., Márk, Z., Zatloukal, P., Szima, B., Albert, I., Juhász, E., Pujol, J. L., Kozielski, J., Baker, N., Smethurst, D., Hei, Y. J., Ashkenazi, A., Stern, H., Amler, L., Pan, Y., and Blackhall, F. (2011) Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer J. Clin. Oncol. 29, 4442-4451
12. Kontermann, R. E. (2012) Antibody-cytokine fusion proteins Arch. Biochem. Biophys. 526, 194-205
13. Wajant, H., Gerspach, J., and Pfizenmaier, K. (2013) Engineering death receptor ligands for cancer therapy Cancer Lett. 332, 163-174
14. de Bruyn, M., Bremer, E., and Helfrich, W. (2013) Antibody-based fusion proteins to target death receptors in cancer Cancer Lett. 332, 175-183
15. Siegemund, M., Pollack, N., Seifert, O., Wahl, K., Vogel, A., Nüssler, A. K., Göttsch, D., Münkel, S., Bantel, H., Kontermann, R. E., and Pfizenmaier, K. (2012) Superior antitumor activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity Cell Death Dis. 3, e295
16. Wahl, K., Siegemund, M., Lehner, F., Vondran, F., Nüssler, A., Länger, F., Krech, T., Kontermann, R. E., Manns, M. P., Schulze-Osthoff, K., Pfizenmaier, K., and Bantel, H. (2013) Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib Hepatology 57, 625-636
17. Seifert, O., Plappert, A., Fellermeier, S., Siegemund, M., Pfizenmaier, K., and Kontermann, R. E. (2013) Tetravalent antibody-scTRAIL fusion proteins with improved properties. 2014 Mol. Cancer Ther. 13, 101-111
18. Mack, K., Rüger, R., Fellermeier, S., Seifert, O., and Kontermann, R. E. (2012) Dual targeting of tumor cells with bispecific single-chain Fv-immunoliposomes Antibodies 1, 199-214
19. Sayers, T. J. (2011) Targeting the extrinsic apoptosis signaling pathway for cancer therapy Cancer Immunol. Immunother. 60, 1173-1180
20. Martinez-Lostao, L., García-Alvarez, F., Basáñez, G., Alegre-Aguarón, E., Desportes, P., Larrad, L., Naval, J., Martínez-Lorenzo, M. J., and Anel, A. (2010) Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis Arthritis Rheum. 62, 2272-2282
21. Lee, A. L. Z., Wang, Y., Pervaiz, S., Fan, W., and Yang, Y. Y. (2011) Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles Macromol. Biosci. 11, 296-307
22. Pearlstein, B., Finniss, S. A., Miller, C., Okhrimenko, H., Kazimirsky, G., Cazacu, S., Lee, J. K., Lemke, N., Brodie, S., Umansky, F., Rempel, S. A., Rosenblum, M., Mikklesen, T., Margel, S., and Brodie, C. (2013) TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo Neuro-Oncol. 15, 29-40
23. Bae, S., Ma, K., Kim, T. H., Lee, E. S., Oh, K. T., Park, E.-S., Lee, L. C., and Youn, Y. S. (2012) Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis inducing ligand and transferrin for targeting multiple tumor types Biomaterials 33, 1536-1546
24. Wheatley, M. A., Cochran, M. C., Eisenbrey, J. R., and Oum, K. L. (2012) Cellular signal transduction can be induced by TRAIL conjugated to microcapsules J. Biomed. Mater. Res., Part A 100, 2602-2611
25. De Miguel, D., Basanez, G., Sanchez, D., Malo, P. G., Marzo, I., Larrad, L., Naval, J., Pardo, J., Anel, A., and Martinez-Lostao, L. (2013) Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells Mol. Pharmacol. 10, 893-904
26. Kim, I., Byeon, H. J., Kim, T. H., Lee, E. S., Oh, K. T., Shin, B. S., Lee, K. C., and Young, Y. S. (2013) Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer Biomaterials 34, 6444-6453
27. de Wilt, L. H., Kroon, J., Jansen, G., de Jong, S., Peters, G. J., and Kruyt, F. A. (2013) Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells? Crit. Rev. Oncol. Hematol. 85, 363-372
28. Slingerland, M., Guchelaar, H. J., and Gelderblom, H. (2012) Liposomal drug formulations in cancer therapy: 15 years along the road Drug Discovery Today 17, 160-166
29. Paszko, E. and Senge, M. O. (2012) Immunoliposomes Curr. Med. Chem. 19, 5239-5277
30. Maeda, H. (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects Bioconjugate Chem. 21, 797-802